<DOC>
	<DOC>NCT00868361</DOC>
	<brief_summary>The purpose of this study is to characterize the chemical breakdown and excretion of talampanel and its break down products in plasma, feces, and urine of healthy human volunteers.</brief_summary>
	<brief_title>A Study to Investigate the Absorption, Metabolism and Excretion of Talampanel</brief_title>
	<detailed_description />
	<criteria>Males, between 18 and 55 years of age, inclusive Body Mass Index range 18.0 to 30.0 kg/m2, inclusive Have NAT2 slow or rapid acetylator genotype In good health as determined by the investigator Negative test for selected drugs of abuse at screening Negative screens for Hepatitis B, Hepatitis C and HIV Sterile or agrees to use an approved method of contraception from Checkin until 45 days following Clinic Discharge Able to comprehend and willing to sign an Informed Consent Form Have 1 to 2 bowel movements per day Significant history or clinical manifestation of any significant metabolic, allergic, skin, liver, kidney, blood, heart or blood vessel, digestive system, brain or psychiatric disorder History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance History of stomach or intestinal surgery or resection History or presence of an abnormal ECG, History of clinically significant alcohol or drug use within 1 year prior to Checkin Participation in more than 1 other radiolabeled investigational study drug trial within 12 months prior to Checkin Exposure to significant radiation within 12 months prior to Checkin Use of any tobacco or nicotinecontaining within 6 months prior to Check in Use of any drugs which may interact with the study drug within 30 days prior to Checkin Participation in any other investigational study drug trial in which receipt of an investigational study drug occurred within 30 days prior to Checkin Use of any prescription medications/products within 14 days prior to Check in Use of any overthecounter, nonprescription drugs within 7 days prior to Checkin Use of grapefruit or grapefruitcontaining foods or beverages within 7 days prior to Checkin Use of alcohol or caffeinecontaining foods or beverages within 72 hours prior to Checkin Donation of blood from 30 days prior to Screening through Study Completion, inclusive, or of plasma from 2 weeks prior to Screening through Study Completion Receipt of blood products within 2 months prior to Checkin Any acute or chronic condition that would limit the subject's ability to complete and/or participate in this clinical study</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Mass Balance</keyword>
	<keyword>Talampanel</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Metabolism</keyword>
	<keyword>Metabolites</keyword>
	<keyword>Healthy Volunteers</keyword>
</DOC>